Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early .
SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy
Trial enrolled patients with advanced cervical cancer regardless of PD-L1 status
Fourth cancer type where Libtayo has positive pivotal data; regulatory submission
Sanofi: Phase 3 trial of Libtayo (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels
Expected to enroll 415 participants; interim results expected in Q3 2021
In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants
PARIS and LEXINGTON, MASS. - March 12, 2021 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. The Companies expect interim results from this trial in the third quarter of 2021.
Parkland Corporation Announces March 2021 Dividend
/EIN News/ CALGARY, Alberta, March 11, 2021 (GLOBE NEWSWIRE) Parkland Corporation (“Parkland”) (TSX:PKI) announces that a dividend of $0.1029 per share will be paid on April 15, 2021 to shareholders of record on March 22, 2021. The dividend will be an eligible dividend for Canadian income tax purposes. The ex-dividend date is March 19, 2021.
Enhanced Dividend Reinvestment Plan
Parkland s enhanced Dividend Reinvestment Plan ( Enhanced DRIP ) allows shareholders to reinvest their cash dividends to purchase additional Parkland shares from treasury at a 5% per share discount to the average of the daily volume weighted average trading prices during the Pricing Period. For further details on the Enhanced DRIP and the Pricing Period, please visit www.parkland.ca/en/investors/dividends.
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.